Annual

medicine

Disc Medicine to Present at the Virtual 62nd American Society of Hematology Annual Meeting

Press release content from PR Newswire. The AP news staff was not involved in its creation.

CAMBRIDGE, Mass., Dec. 2, 2020 /PRNewswire/ — Disc Medicine, a biotechnology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating hematologic diseases, today announced that preclinical data from two pipeline programs that modulate the hepcidin pathway will be presented at the 62nd American Society of Hematology (ASH) Annual Meeting & Exposition, which will be held virtually December 5-8, 2020.

Details of the presentations are as follows:

Abstract Number: 1690
Title: DISC-a, the First in a Novel Class of Potent and Selective Matriptase-2 Inhibitors for the Treatment of Hematologic Disorders Characterized By Low Hepcidin
Date: Sunday, December 6, 2020, 7:00 AM-3:30 PM EST
Session: 102. Regulation of Iron Metabolism: Poster II
Presenter: Vu Hong, PhD, Director and Project Leader

Abstract Number: 2599
Title: DISC-0974, a Novel, First-in-Class, Anti-Hemojuvelin Monoclonal Antibody Decreases Hepcidin and Increases Transferrin Saturation in a Non-Human Primate Model of Cytokine (IL-6) Induced Hypoferremia
Date: Monday, December 7, 2020, 7:00 AM-3:30 PM EST
Session: 102. Regulation of Iron Metabolism: Poster III
Presenter: Maria Beconi, PhD, SVP of Translational Research and Development

Full abstracts are currently available through the ASH conference website: www.hematology.org/Annual-Meeting/Abstracts/.

About Disc Medicine
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Currently focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.

View original content to download multimedia: http://www.prnewswire.com/news-releases/disc-medicine-to-present-at-the-virtual-62nd-american-society-of-hematology-annual-meeting-301185107.html

SOURCE Disc Medicine

Source Article

Read More
medicine

Disc Medicine to Present at the Piper Sandler 32nd Annual Healthcare Conference

CAMBRIDGE, Mass., Nov. 23, 2020 /PRNewswire/ — Disc Medicine, a hematology company dedicated to the discovery and development of novel therapeutic candidates for serious and debilitating diseases, announced it will participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference.

Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is advancing first-in-class therapies to transform the treatment of hematologic diseases. (PRNewsfoto/Disc Medicine)

A pre-recorded presentation by John Quisel, J.D., Ph.D., Chief Executive Officer of Disc Medicine, will be available beginning on Monday, November 23 at 10:00 am Eastern Standard Time. A link to the presentation will be provided in the “News & Events” section of Disc Medicine’s website at www.discmedicine.com.

About Disc Medicine
Disc Medicine is a hematology company harnessing new insights in hepcidin biology to address ineffective red blood cell production (erythropoiesis) in hematologic diseases. Currently focused on the hepcidin pathway, the master regulator of iron metabolism, Disc is developing a portfolio of first-in-class therapeutic candidates to transform the treatment of hematologic diseases. For more information, visit www.discmedicine.com.

 

Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/disc-medicine-to-present-at-the-piper-sandler-32nd-annual-healthcare-conference-301178870.html

SOURCE Disc Medicine

Source Article

Read More
health

Change Healthcare to Present at the Credit Suisse 29th Annual Healthcare Conference

Change Healthcare Inc. (Nasdaq: CHNG), a leading independent healthcare technology company, today announced its participation in a virtual fireside chat via webcast at the Credit Suisse 29th Annual Healthcare Conference on Wednesday, Nov. 11, 2020 at 11:00 a.m. Eastern Time.

The live webcast and more information about this event may be accessed by visiting the Events and Presentations tab at http://ir.changehealthcare.com. The webcast replay will be available approximately 48 hours after the live webcast ends and will be accessible for 90 days following the conference.

About Change Healthcare

Change Healthcare (Nasdaq: CHNG) is a leading independent healthcare technology company, focused on insights, innovation, and accelerating the transformation of the U.S. healthcare system through the power of the Change Healthcare Platform. We provide data and analytics-driven solutions to improve clinical, financial, administrative, and patient engagement outcomes in the U.S. healthcare system.

Learn more at changehealthcare.com.

CHNG-IR

View source version on businesswire.com: https://www.businesswire.com/news/home/20201028005185/en/

Contacts

Evan Smith, CFA
Investor Relations
404-338-2225
[email protected]

Source Article

Read More
health

Annual stone crab claw harvest begins in Florida

MARATHON, Fla. (AP) — Florida’s annual stone crab claw harvest has started amid new rules aimed at protecting future stocks and concerns about demand for claws due to the COVID-19 pandemic.

New regulations, enforced by the Florida Fish and Wildlife Conservation Commission, include increasing the minimum size of a harvested claw from 2 3/4 inches (7 centimeters) to 2 7/8 inches (7.3 centimeters); reducing the harvest season by two weeks and modifying traps to have a 2 3/16-inch (5.5-centimeter) escape ring. The season started Thursday and ends May 1.

Trap modifications must be completed by the 2023-2024 season, but Gary Graves, vice president of Keys Fisheries, one of the state’s largest processors of the tasty claws, said many commercial fishermen’s traps in the Florida Keys are already compliant.

He said commercial fishermen around the state worked with FWC officials to institute the new rules to ensure future harvests.


“We’re in favor of this (new regulations) to rebuild the fishery,” Graves said, adding that about 2.1 million pounds of claws were harvested last year around Florida. “Probably in four or five years, we’ll be able to start catching three or three-and-a-half million pounds (annually) like we used to.”

Graves said the COVID-19 pandemic has fishermen on edge because most commercially harvested claws are sold to restaurants across Florida.

“Retail, I think, is strong,” Graves said. “We see a lot of people ordering (seafood) online or going to the grocery store and buying and eating at home.

“But we just don’t know what restaurants are going to do this year in Florida, which are the largest consumers of the crab,” he said.

Source Article

Read More